BioCentury | Mar 26, 2015
Distillery Therapeutics

Therapeutics: Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)

...Endocrine/metabolic disease INDICATION: Diabetes; obesity In vitro and mouse studies suggested the mitochondrial peptide MOTS-c could...
...open reading frames (sORFs) in mitochondrial DNA (mtDNA) identified a sequence encoding the 16-mer peptide MOTS-c...
...expressed in skeletal muscle and other rodent tissues. In human embryonic kidney cells, over-expression of MOTS-c...
BioCentury | Mar 26, 2015
Product R&D

Raising the CohBar

...metabolism and inflammation. Specifically, MOTS-c activated AMPK-stimulated glucose clearance. In mice fed a high-fat diet, MOTS-c...
...peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism (2015) Figures MOTS-c...
...function.MOTS-c is transcribed from the mitochondrial chromosome and originates from the 12S rRNA locus. The MOTS-c...
BioCentury | Jan 12, 2004
Company News

Gene Logic, Sumitomo deal

Sumitomo renewed its 2001 subscription to GLGC's information services for three years (see BioCentury, Jan. 16, 2001). The deal includes access to GLGC's BioExpress gene expression database, Ascenta System of pre-formatted summary gene expression data,...
BioCentury | Feb 3, 2003
Finance

Bio-warfare plays

Bio-warfare plays Company Approach 1/31 cls Wk chg % chg Mkt cap chg ($M) 1/31 mkt cap ($M) Int'l BioChemical (IBCL) Antimicrobial $0.15 $0.13 625% $10.0 $11.6 Antex (ANX) Vaccine $0.57 $0.08 16% $1.0 $7.1...
BioCentury | Jul 29, 2002
Company News

Amersham, Motorola Inc. deal

AHM paid $20 million for CodeLink (Tempe, Ariz.), the bioarray unit of MOT's life science business. AHM expects to continue manufacturing at the Tempe plant and to transfer key MOT personnel to AHM. Amersham plc...
BioCentury | Jul 29, 2002
Strategy

Ebsworth's quick decision on Zavesca

Rather than develop a post-marketing pharmacovigilance system for its Zavesca Gaucher disease treatment and build a sales and marketing force from the ground up, Oxford Glycosciences plc has opted to put these launch responsibilities in...
BioCentury | Jul 25, 2002
Company News

Motorola exiting research bioarrays

MOT said it is exiting the research microarray market and is selling the CodeLink (Tempe, Ariz.) bioarray unit of its life sciences business to Amersham (AHM; LSE:AHM) for $20 million. AHM expects to continue manufacturing...
BioCentury | Oct 29, 2001
Strategy

Holding all the chips

The microarray space has thinned out, as Corning Inc. and Incyte Genomics Inc. have exited the arena, while Hyseq Inc. has moved into alliance with Affymetrix Inc. to develop high speed DNA sequencing chips. The...
BioCentury | Oct 25, 2001
Company News

Incyte restructures

INCY will divest or halt its custom genomics businesses, including microarray production and transgenics, to focus on its LifeSeq database. INCY also will discontinue by year end its internal therapeutic SNP discovery program. Furthermore, INCY...
BioCentury | Oct 22, 2001
Finance

Bio-defense plays

Bio-defense plays Company Wkly $ chg Wkly % chg 10/19 cls 10/19 mkt cap Mkt cap $ since 9/10 % chg Abgenix (ABGX) $0.89 3% $28.31 $2,433.2M $109.2M 5% Acambis (LSE:ACM, ACAM)(A) $3.90 14% $32.00...
Items per page:
1 - 10 of 38